|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | C07D 471/04 | (2006.01) |
| A61K 31/437 | (2006.01) | ||
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 3140303 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15724351.0 |
| Date of filing the European patent application | 2015-05-05 | |
| (97) | Date of publication of the European application | 2017-03-15 |
| (45) | Date of publication and mention of the grant of the patent | 2018-03-28 |
| (46) | Date of publication of the claims translation | 2018-05-25 |
| (86) | Number | PCT/GB2015/051312 |
| Date | 2015-05-05 |
| (87) | Number | WO 2015/170081 |
| Date | 2015-11-12 |
| (30) | Number | Date | Country code |
| 201461990232 P | 2014-05-08 | US |
| (72) |
BARLAAM, Bernard Christophe, GB
PIKE, Kurt Gordon, GB
|
| (73) |
Astrazeneca AB,
151 85 Södertälje,
SE
|
| (74) |
Liudmila GERASIMOVIČ,
IĮ "Liudmila Gerasimovič, Patentinis patikėtinis", Vingrių g. 13-42, LT-01141 Vilnius,
LT
|
| (54) | Imidazo[4,5-C]chinolin-2-ono junginiai ir jų panaudojimas vėžio gydymui |
| IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER |
| Payment date | Validity (years) | Amount | |
| 2023-04-24 | 9 | 208.00 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2024-05-05 |